A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer (RANGE)
The main purpose of this study is to evaluate the safety and efficacy of the study drug ramucirumab in combination with docetaxel in participants with urothelial cancer who failed prior platinum-based therapy.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participant must have urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis confirmed by histology or cytology
Participant must have disease progression while on a platinum containing regimen in the first-line setting or within 14 months after completing the first-line platinum regimen
Participant must be willing to provide blood, urine, and tissue samples for research purposes
Participants Must Not:
Participant must not have received more than one prior systemic chemotherapy regimen for metastatic disease
Participant must not have received radiation therapy within 4 weeks (4 weeks) prior to first dose of study drug or has not recovered from toxic effects of the treatment that was given >4 weeks prior to first dose of study drug
Participant must not have a concurrent malignancy or had another malignancy within 5 years (5 years) of study enrollment
Participant must not have HIV infection or acquired immunodeficiency syndrome-related illness
Participant must not be pregnant or lactating
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo